Company
ValiRx PLC
LON:VAL
ValiRx is a drug development company, which focuses on the translation of scientific innovation into clinical candidates for cancer, related conditions and women’s health. The company's specialised business model connects science, finance and commerce to accelerate early-stage drug development. It identifies proprietary and novel drug candidates with the potential to improve patient lives, providing the expertise and investment required for optimised development and value creation.
310 stories · page 11 of 16
Archive
Proactive news round-up: ValiRx, ITM Power, Tharisa ...
A glance at some of the stories on the Proactive newswire today.
Malvern top of the class after tie-up with Singaporean tech group
Some of the main news-driven share price changes at 3.15pm
ValiRx prostate cancer drug delivers eye-catching early results
“[We are] entering a very exciting phase, which should result in the crystallisation of substantial value,” said chief executive, Dr Satu Vainikka.
FTSE 100 hits 10th successive record high close
FTSE 100 shares appear positively related to the Nasdaq as the London ticker again hits a fresh record high on Wednesday - its tenth successive
Archive
Proactive news round-up: Windar Photonics, Mkango Resources, San Leon Energy …
A glance at some of the stories on the Proactive newswire today
Yorkville converts loan notes into ValiRx shares
The notes were converted at 5.625p a share, versus a current share price of 5.15p..
Archive
Proactive News round-up: Service Power, Green Dragon Gas, Plexus ....
A glance at today's headlines on the Proactive newswire ...
Archive
Proactive news round-up: Akers Biosciences, Base Resources, Rambler Metals...
A glance at some of the main stories on the Proactive newswire today
Archive
Proactive news round-up: Sound Energy, Matals Exploration, Acal ...
A snapshot of the stories on the Proactive newswire today
ValiRx's lead candidate study to be expanded
The trial is a phase I/II dose escalation study to assess safety and tolerability
Proactive news summary: Sirius Minerals stands out on big day for funding
Also covered: Blur, Eckoh, Eurasia, FairFX, H&T, Rosslyn, KrisEnergy, Sierra Rutile, Tern, ValiRx, Xtract Resources
ValiRx encouraged by progress in lung cancer trial
Members of the ValiSeek joint venture made a site visit to the clinic in Tbilisi, Georgia
Funding boost for Sirius Minerals and 88 Energy, but its GAME OVER for Xcite
Suddenly there’s cash swilling around the AIM natural resources sector, but the return of positive sentiment is too little too late for Xcite Energy.
ValiRx receives new patents in Japan and US for lead compounds
The patents relate to the firm's compounds VAL201 and VAL401, which are currently in clinical trials